Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Aug 15;198(4):465-9.
doi: 10.1086/590160.

Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission

Tamara S Flys  1 , Michelle S McConnell, Flavia Matovu, Jessica D Church, Danstan Bagenda, Leila Khaki, Paul Bakaki, Michael C Thigpen, Chineta Eure, Mary Glenn Fowler, Susan H Eshleman
Affiliations

Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission

Tamara S Flys et al. J Infect Dis. .

Abstract

Single-dose (SD) nevirapine (NVP) significantly reduces mother-to-child transmission of human immunodeficiency virus (HIV). We analyzed NVP resistance after receipt of SD NVP in 57 previously SD NVP-naive women, in 34 SD NVP-experienced women, and in 17 HIV-infected infants. The proportion of women infected with variants with resistance mutations, the types of mutations detected, and the frequency and level of K103N were similar in the two groups of women at 6 weeks and 6 months post partum. NVP resistance was detected in a similar proportion of infants born to SD NVP-naive versus SD NVP-experienced women. Repeated use of SD NVP to prevent HIV transmission does not appear to influence NVP resistance.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement

None of the authors has a commercial or other association that might pose a conflict of interest with the following exception: Dr. Susan Eshleman is a co-inventor of the LigAmp assay and Johns Hopkins University has filed a patent application with the US-Patent and Trademark Office. The inventors may receive royalty payments if the patent is awarded and licensed.

References

    1. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012) AIDS. 2001;15:1951–1957. - PubMed
    1. Johnson JA, Li JF, Morris L, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis. 2005;192:16–23. - PubMed
    1. Flys T, Nissley DV, Claasen CW, et al. Sensitive drug resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after single dose NVP: HIVNET 012. J Infect Dis. 2005;192:24–29. - PubMed
    1. Martinson NA, Morris L, Gray G, et al. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr. 2007;44:148–153. - PubMed
    1. Flys TS, Donnell D, Mwatha A, et al. Persistence of K103N-containing HIV-1 variants after single dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis. 2007;195:11–15. - PubMed

Publication types

MeSH terms